B. Metzler seel. Sohn & Co. AG Increases Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

B. Metzler seel. Sohn & Co. AG grew its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 35.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,049 shares of the company’s stock after acquiring an additional 8,909 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Dr. Reddy’s Laboratories were worth $538,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Robeco Institutional Asset Management B.V. boosted its holdings in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Aikya Investment Management Ltd grew its stake in shares of Dr. Reddy’s Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock worth $88,590,000 after purchasing an additional 4,523,303 shares during the period. Vanguard Group Inc. increased its holdings in shares of Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock valued at $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Dr. Reddy’s Laboratories by 462.1% in the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company’s stock valued at $44,444,000 after purchasing an additional 2,313,987 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in Dr. Reddy’s Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after buying an additional 1,977,419 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Price Performance

Dr. Reddy’s Laboratories stock opened at $12.37 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $10.32 billion, a PE ratio of 19.69 and a beta of 0.48. The firm’s 50-day simple moving average is $13.33 and its 200 day simple moving average is $14.51. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.36 and a 52 week high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.